Curcumin and demethoxycurcumin inhibit NLRP3 inflammasome activation and reduce IL-1β production through direct binding to NLRP3 protein and suppression of NF-κB signaling. This addresses the hyperinflammatory phenotype in mevalonic aciduria by targeting the downstream inflammatory cascade triggered by mevalonate kinase deficiency.